Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has shown a significant increase in stock price and trading volume, indicating positive market sentiment despite a decline in net profit [1]. Financial Performance - As of Q1 2025, the company reported total revenue of 628 million yuan, representing a year-on-year growth of 18.78% [1]. - The net profit attributable to shareholders was 23.06 million yuan, a decrease of 29.15% year-on-year [1]. - The non-recurring net profit was 22.15 million yuan, down 27.95% year-on-year [1]. - The current ratio is 1.173, the quick ratio is 0.786, and the debt-to-asset ratio stands at 50.71% [1]. Market Activity - On August 4, 2025, the stock closed at 20.82 yuan, up 9.98%, with a turnover rate of 21.76% and a trading volume of 621,200 hands, amounting to a transaction value of 1.203 billion yuan [1]. - The net inflow of main funds was 160 million yuan, accounting for 13.28% of the transaction value, with large orders contributing 132 million yuan [1]. Company Background - Jiangsu Lianhuan Pharmaceutical Co., Ltd. was established in 2000 and is located in Yangzhou, primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 2.854 billion yuan and a paid-in capital of 40 million yuan [1][2]. - The legal representative of the company is Qian Zhenhua [1]. Investment and Intellectual Property - The company has made investments in 13 enterprises and participated in 5,000 bidding projects [2]. - It holds 46 trademark registrations and 240 patent applications, along with 559 administrative licenses [2].

Core Viewpoint - On August 4, Lianhuan Pharmaceutical experienced a 9.98% increase in stock price, reaching 20.82 CNY per share, with a trading volume of 1.163 billion CNY and a turnover rate of 21.09%, resulting in a total market capitalization of 5.943 billion CNY [1] Company Overview - Jiangsu Lianhuan Pharmaceutical Co., Ltd. is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise. The company integrates research and development, production, and sales, specializing in various forms of medications including tablets, hard capsules (including hormone types), suppositories (hormone types), and granules, with an annual production capacity of 5 billion pieces [1] - The company's main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, with over 100 varieties and specifications. Key products include the first-class new drug Aipulete, the second-class new drug Ebastine, and core products like Nifedipine. The company boasts a high-end R&D team of nearly 200 members and multiple R&D platforms [1] Financial Performance - For the first quarter of 2025 (January to March), Lianhuan Pharmaceutical reported a revenue of 628 million CNY, representing a year-on-year growth of 18.78%. However, the net profit attributable to shareholders was 23.0596 million CNY, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders for Lianhuan Pharmaceutical was 30,300, with an average of 9,416 circulating shares per person [1]

风险提示：股市有风险，投资需谨慎。 截至13时46分，联环药业涨停，最新价20.82元，封板资金达2.51亿元，成交额11.64亿元，换手率 21.12%。公司所属化学制药行业，总市值59.43亿元。8月1日创新药概念板块表现强势，联环药业与汉 商集团双双涨停，显示市场对该领域的关注度较高。 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. experienced a stock price increase of 6.5% on August 4, reaching 20.16 yuan per share, with a trading volume of 904 million yuan and a turnover rate of 16.63%, resulting in a total market capitalization of 5.755 billion yuan [1] Company Overview - Jiangsu Lianhuan Pharmaceutical is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise. The company integrates research and development, production, and sales, specializing in various pharmaceutical forms including tablets, hard capsules (including hormone types), suppositories (hormone types), and granules, with an annual production capacity of 5 billion pieces [1] - The company's main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, with over 100 varieties and specifications. Key products include the first-class new drug Aipulete, the second-class new drug Ebastine, and core products like Felodipine. The company boasts a high-end R&D team of nearly 200 people and multiple R&D platforms [1] Financial Performance - For the first quarter of 2025, Jiangsu Lianhuan Pharmaceutical reported an operating income of 628 million yuan, representing a year-on-year growth of 18.78%. However, the net profit attributable to shareholders was 23.0596 million yuan, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders for Lianhuan Pharmaceutical was 30,300, with an average of 9,416 circulating shares per person [1]

Market Overview - The Shanghai Composite Index fell by 0.94% this week, with six industries experiencing gains, led by the pharmaceutical and biotechnology sector, which rose by 2.95% [1] - The coal and non-ferrous metals industries saw the largest declines, with drops of 4.67% and 4.62% respectively [1] Fund Flow Analysis - A total of 211.86 billion yuan was net withdrawn from the two markets this week, with only the banking sector seeing a net inflow of 4.33 billion yuan [1] - The non-ferrous metals industry had the highest net outflow, totaling 25.99 billion yuan, followed by the computer industry with a net outflow of 20.45 billion yuan [1][2] Pharmaceutical and Biotechnology Sector - The pharmaceutical and biotechnology sector had a net outflow of 4.68 billion yuan this week, despite a price increase of 2.95% [3] - Out of 474 stocks in this sector, 323 stocks rose, with notable gainers including Nanjing New Pharmaceutical (up 78.01%), Lide Man (up 46.45%), and Chenxin Pharmaceutical (up 40.88%) [3] - The sector also saw 36 stocks with net outflows exceeding 100 million yuan, with WuXi AppTec leading at 1.98 billion yuan [3][4] Top Gainers and Losers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: up 29.52% with a net inflow of 1.01 billion yuan - Anke Bio: up 25.93% with a net inflow of 0.36 billion yuan - Lianhuan Pharmaceutical: up 15.99% with a net inflow of 0.34 billion yuan [3] - The top losers included: - WuXi AppTec: down 4.64% with a net outflow of 1.98 billion yuan - Borui Pharmaceutical: down 0.14% with a net outflow of 0.71 billion yuan - Kanglong Chemical: up 0.33% with a net outflow of 0.51 billion yuan [4]

Core Insights - The avian influenza concept sector saw an increase of 1.62%, ranking fourth among concept sectors in terms of growth, with 20 stocks rising, including Zhongsheng Pharmaceutical, Lianhuan Pharmaceutical, and Yongshun Biological, which rose by 7.49%, 7.31%, and 6.32% respectively [1] - The sector experienced a net inflow of 938 million yuan from main funds, with 10 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 30 million yuan, led by Zhongsheng Pharmaceutical with a net inflow of 533 million yuan [1] Sector Performance - The top-performing concept sectors included: - Animal vaccines: +2.22% - DRG/DIP: +1.87% - BC batteries: +1.71% - Avian influenza: +1.62% - Medical waste treatment: +1.61% [1] Fund Flow Analysis - Leading stocks in terms of fund inflow ratios included: - Lianhuan Pharmaceutical: 21.80% - Zhongsheng Pharmaceutical: 15.06% - Taiji Group: 9.94% [2] - The top stocks by main fund flow included: - Zhongsheng Pharmaceutical: 532.84 million yuan - Lianhuan Pharmaceutical: 278.91 million yuan - Taiji Group: 97.84 million yuan [2][3]

通过天眼查大数据分析，江苏联环药业股份有限公司共对外投资了13家企业，参与招投标项目5000次， 知识产权方面有商标信息46条，专利信息240条，此外企业还拥有行政许可554个。 来源：金融界 联环药业最新一期业绩显示，截至2025一季报，公司营业总收入6.28亿元、同比增长18.78%，归属净利 润2305.96万元，同比减少29.15%，扣非净利润2215.05万元，同比减少27.95%，流动比率1.173、速动比 率0.786、资产负债率50.71%。 天眼查商业履历信息显示，江苏联环药业股份有限公司，成立于2000年，位于扬州市，是一家以从事医 药制造业为主的企业。企业注册资本28545.627万人民币，实缴资本4000万人民币。公司法定代表人为 钱振华。 金融界消息 截至2025年8月1日收盘，联环药业（600513）报收于18.93元，上涨7.31%，换手率 23.51%，成交量67.10万手，成交金额12.79亿元。 资金流向方面，今日主力资金净流入2.67亿元，占比成交额20.88%。其中，超大单净流入2.89亿元、占 成交额22.63%，大单净流出2234.03万元、占成交额1.75%，中单 ...

Group 1 - The main focus of the article is on the net inflow and outflow of capital in various sectors, highlighting significant movements in the market on a specific day [1] - The power equipment sector saw the highest net inflow of 15.22 billion, followed by the new energy industry with 9.62 billion and the automotive sector with 6.19 billion [2] - The computer sector experienced the largest net outflow of 34.09 billion, with the electronics and non-ferrous metals sectors also seeing significant outflows of 31.71 billion and 19.37 billion respectively [3] Group 2 - Individual stocks with the highest net inflow included Jiejia Weichuang with 5.25 billion, Hikvision with 4.45 billion, and Beiqi Blue Valley with 4.10 billion [4] - New Yisheng had the largest net outflow at 5.77 billion, followed by Northern Rare Earth with 5.58 billion and Yingweike with 5.57 billion [5]

格隆汇8月1日｜医药板块持续大涨，众生药业、联环药业、汉商集团等近10只个股涨停，悦康药业涨逾 12%，维康药业涨逾9%。 ...

Group 1 - The core viewpoint of the news is the significant rise in virus prevention concept stocks, particularly in response to the release of the 2025 treatment plan for Chikungunya virus, which has led to increased investor interest in related companies [1][2] - Companies such as Lide Man, Lianhuan Pharmaceutical, and Rejing Bio have seen substantial stock price increases, with Lide Man reaching a 20% limit up and Lianhuan Pharmaceutical achieving a nearly 10% increase [1][2] - The treatment plan emphasizes preventive measures against Chikungunya virus, including mosquito control and personal protective measures, highlighting the ongoing public health concern and the lack of available vaccines in China [1] Group 2 - Specific stock performance data shows Lide Man with a 20.03% increase, Lianhuan Pharmaceutical with a 9.98% increase, and Rejing Bio with a 9.25% increase, indicating strong market reactions [2] - Year-to-date performance reveals that Rejing Bio has surged by 244.50%, while Lianhuan Pharmaceutical has increased by 97.68%, showcasing the potential for continued growth in the sector [2] - Other companies such as Zhongsheng Pharmaceutical and Maiwei Niuwu also experienced notable gains, further indicating a broader trend in the virus prevention sector [1][2]